Svetlana Mojsov, Joel Habener, and Dan Drucker.

ALZHEIMER'S disease; PARKINSON'S disease; GASTROINTESTINAL hormones; SEMAGLUTIDE

This article from TIME Magazine discusses the groundbreaking research that led to the development of weight-loss medications like Wegovy. Scientists in Europe and the U.S. made a connection between insulin and incretins, which are gut hormones known as glucagons. Researchers at the University of Copenhagen and Massachusetts General Hospital played key roles in understanding the effects of glucagon and developing GLP-1-based medications. These medications are now approved in the U.S. to treat diabetes and obesity, and there is ongoing research into their potential benefits for other diseases like Alzheimer's and Parkinson's. [Extracted from the article]

Copyright of TIME Magazine is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)